Esperion to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 04 2017 - 5:00PM
Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management
company focused on developing and commercializing complementary
oral therapies for the treatment of patients with elevated low
density lipoprotein cholesterol (LDL-C), today announced that
president and chief executive officer, Tim M. Mayleben, will
present at the 35th Annual J.P. Morgan Healthcare Conference in San
Francisco, CA on Tuesday, January 10, 2017 at 3:00 p.m. Pacific
Time/6:00 p.m. Eastern Time.
A live, listen-only webcast of the presentation can be accessed
on the investor relations section of the Esperion website at
www.esperion.com. A webcast replay of the presentation will be
archived on the Company's website for 90 days following the
event.
About Bempedoic Acid
With a targeted mechanism of action, bempedoic acid is a
first-in-class ACL inhibitor that reduces cholesterol biosynthesis
and lowers elevated levels of LDL-C by up-regulating the LDL
receptor, but with reduced potential for muscle-related side
effects. Completed Phase 1 and 2 studies in more than 800 patients
treated with bempedoic acid have produced clinically relevant LDL-C
lowering results of up to 30 percent as monotherapy, approximately
50 percent in combination with ezetimibe, and an incremental 20 to
22 percent when added to stable statin therapy.
Esperion's Commitment to Patients with
Hypercholesterolemia
In the United States, 78 million people, or more than 20 percent
of the population, have elevated LDL-C; an additional 73 million
people in Europe and 30 million people in Japan also live with
elevated LDL-C. Esperion's mission as the lipid management company
is to provide patients and physicians with a new convenient and
complementary oral therapy to significantly reduce elevated levels
of LDL-C in patients inadequately treated with current
lipid-modifying therapies. Esperion-discovered and developed,
bempedoic acid is a targeted LDL-C lowering therapy in Phase 3
development. The Company has two Phase 3 products with plans to
develop bempedoic acid as a monotherapy as well as a fixed dose
combination (FDC) with ezetimibe, with a particular focus on
patients inadequately treated with current lipid-modifying
therapies. It is estimated that approximately 5-20 percent of
patients who are prescribed statins are only able to tolerate less
than the lowest approved daily starting dose of their statin
("statin intolerant").
About Esperion
Esperion Therapeutics, Inc. is the lipid management company
focused on developing and commercializing convenient and
complementary oral therapies for the treatment of patients with
elevated LDL-C. Through scientific and clinical excellence, and a
deep understanding of cholesterol biology, the experienced lipid
management team at Esperion is committed to developing new LDL-C
lowering therapies that will make a substantial impact on reducing
global cardiovascular disease; the leading cause of death around
the world. Bempedoic acid, the Company's lead product candidate,
has a targeted mechanism of action that significantly reduces
elevated LDL-C levels in patients with hypercholesterolemia,
including patients inadequately treated with current
lipid-modifying therapies. For more information, please
visit www.esperion.com and follow us on Twitter
at https://twitter.com/EsperionInc.
Media Contact:
Elliot Fox
W2O Group
212.257.6724
efox@w2ogroup.com
Investor Contact:
Mindy Lowe
Esperion Therapeutics, Inc.
734.887.3903
mlowe@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024